InvestorsHub Logo

PJO

Followers 5
Posts 289
Boards Moderated 0
Alias Born 08/15/2013

PJO

Re: None

Thursday, 03/30/2017 10:21:57 AM

Thursday, March 30, 2017 10:21:57 AM

Post# of 1121
Phase 3 news
09:29 AM EDT, 03/30/2017 (MT Newswires) -- Acasti Pharma(ACST) gained more than 11% in premarket trade Thursday after it said it would proceed with its Phase 3 development program for CaPre, following its recent end-of-Phase 2 meeting with the U.S. Food and Drug Administration.

CaPre is an omega-3 drug derived of krill oil being developed for the treatment of patients with hypertriglyceridemia, a metabolic condition that contributes to the risk of cardiovascular disease and pancreatitis.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ACST News